When I read your arguments, I ask myself whether you even know how an R/M is created and what the point of a shell / takeover / name change etc. is? D. Lazar is one of the most successful R/M makers on the OTC and he has sold the EXBX Custodian to new owners who want to bring EXBX to life. EXBX can go the same way as GOFF. EXBX is on the right track. A formal error in the name change delayed the schedule somewhat. I see EXBX with $0.5 potential. Where there is enormous potential, there is also risk. If everything were save, EXBX would already be trading $0.2 $0.5 and not $012 $02 range. I'm patient and looking forward to what's to come.
News 
Market Data 
Discover 
